Global Neuroblastoma Chemotherapy Drugs Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028
The Neuroblastoma Chemotherapy Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Neuroblastoma Chemotherapy Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Hospital accounting for % of the Neuroblastoma Chemotherapy Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Cyclophosphamide segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Neuroblastoma Chemotherapy Drugs include Baxter Healthcare, Ingenus Pharmaceuticals, ANI Pharmaceuticals, Teva Pharmaceuticals, and Qilu Pharmaceutical, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Neuroblastoma Chemotherapy Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Chapter 1, to describe Neuroblastoma Chemotherapy Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Neuroblastoma Chemotherapy Drugs, with price, sales, revenue and global market share of Neuroblastoma Chemotherapy Drugs from 2019 to 2022.
Chapter 3, the Neuroblastoma Chemotherapy Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neuroblastoma Chemotherapy Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Neuroblastoma Chemotherapy Drugs market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Neuroblastoma Chemotherapy Drugs.
Chapter 13, 14, and 15, to describe Neuroblastoma Chemotherapy Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Neuroblastoma Chemotherapy Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Hospital accounting for % of the Neuroblastoma Chemotherapy Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Cyclophosphamide segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Neuroblastoma Chemotherapy Drugs include Baxter Healthcare, Ingenus Pharmaceuticals, ANI Pharmaceuticals, Teva Pharmaceuticals, and Qilu Pharmaceutical, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Neuroblastoma Chemotherapy Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
- Cyclophosphamide
- Cisplatin or Carboplatin
- Vincristine
- Doxorubicin (Adriamycin)
- Etoposide
- Other
- Hospital
- Clinic
- Other
- Baxter Healthcare
- Ingenus Pharmaceuticals
- ANI Pharmaceuticals
- Teva Pharmaceuticals
- Qilu Pharmaceutical
- Pfizer
- Hikma Pharmaceuticals
- Fresenius Kabi
- Accord Healthcare
- Viatris
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Neuroblastoma Chemotherapy Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Neuroblastoma Chemotherapy Drugs, with price, sales, revenue and global market share of Neuroblastoma Chemotherapy Drugs from 2019 to 2022.
Chapter 3, the Neuroblastoma Chemotherapy Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neuroblastoma Chemotherapy Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Neuroblastoma Chemotherapy Drugs market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Neuroblastoma Chemotherapy Drugs.
Chapter 13, 14, and 15, to describe Neuroblastoma Chemotherapy Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 MARKET OVERVIEW
1.1 Neuroblastoma Chemotherapy Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Neuroblastoma Chemotherapy Drugs Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Cyclophosphamide
1.2.3 Cisplatin or Carboplatin
1.2.4 Vincristine
1.2.5 Doxorubicin (Adriamycin)
1.2.6 Etoposide
1.2.7 Other
1.3 Market Analysis by Application
1.3.1 Overview: Global Neuroblastoma Chemotherapy Drugs Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Neuroblastoma Chemotherapy Drugs Market Size & Forecast
1.4.1 Global Neuroblastoma Chemotherapy Drugs Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Neuroblastoma Chemotherapy Drugs Sales in Volume (2017-2028)
1.4.3 Global Neuroblastoma Chemotherapy Drugs Price (2017-2028)
1.5 Global Neuroblastoma Chemotherapy Drugs Production Capacity Analysis
1.5.1 Global Neuroblastoma Chemotherapy Drugs Total Production Capacity (2017-2028)
1.5.2 Global Neuroblastoma Chemotherapy Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Neuroblastoma Chemotherapy Drugs Market Drivers
1.6.2 Neuroblastoma Chemotherapy Drugs Market Restraints
1.6.3 Neuroblastoma Chemotherapy Drugs Trends Analysis
2 MANUFACTURERS PROFILES
2.1 Baxter Healthcare
2.1.1 Baxter Healthcare Details
2.1.2 Baxter Healthcare Major Business
2.1.3 Baxter Healthcare Neuroblastoma Chemotherapy Drugs Product and Services
2.1.4 Baxter Healthcare Neuroblastoma Chemotherapy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Ingenus Pharmaceuticals
2.2.1 Ingenus Pharmaceuticals Details
2.2.2 Ingenus Pharmaceuticals Major Business
2.2.3 Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
2.2.4 Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 ANI Pharmaceuticals
2.3.1 ANI Pharmaceuticals Details
2.3.2 ANI Pharmaceuticals Major Business
2.3.3 ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
2.3.4 ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Teva Pharmaceuticals
2.4.1 Teva Pharmaceuticals Details
2.4.2 Teva Pharmaceuticals Major Business
2.4.3 Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
2.4.4 Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Qilu Pharmaceutical
2.5.1 Qilu Pharmaceutical Details
2.5.2 Qilu Pharmaceutical Major Business
2.5.3 Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Product and Services
2.5.4 Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Pfizer
2.6.1 Pfizer Details
2.6.2 Pfizer Major Business
2.6.3 Pfizer Neuroblastoma Chemotherapy Drugs Product and Services
2.6.4 Pfizer Neuroblastoma Chemotherapy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Hikma Pharmaceuticals
2.7.1 Hikma Pharmaceuticals Details
2.7.2 Hikma Pharmaceuticals Major Business
2.7.3 Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
2.7.4 Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Fresenius Kabi
2.8.1 Fresenius Kabi Details
2.8.2 Fresenius Kabi Major Business
2.8.3 Fresenius Kabi Neuroblastoma Chemotherapy Drugs Product and Services
2.8.4 Fresenius Kabi Neuroblastoma Chemotherapy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Accord Healthcare
2.9.1 Accord Healthcare Details
2.9.2 Accord Healthcare Major Business
2.9.3 Accord Healthcare Neuroblastoma Chemotherapy Drugs Product and Services
2.9.4 Accord Healthcare Neuroblastoma Chemotherapy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Viatris
2.10.1 Viatris Details
2.10.2 Viatris Major Business
2.10.3 Viatris Neuroblastoma Chemotherapy Drugs Product and Services
2.10.4 Viatris Neuroblastoma Chemotherapy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 NEUROBLASTOMA CHEMOTHERAPY DRUGS BREAKDOWN DATA BY MANUFACTURER
3.1 Global Neuroblastoma Chemotherapy Drugs Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Neuroblastoma Chemotherapy Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Neuroblastoma Chemotherapy Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Neuroblastoma Chemotherapy Drugs Manufacturer Market Share in 2021
3.4.2 Top 6 Neuroblastoma Chemotherapy Drugs Manufacturer Market Share in 2021
3.5 Global Neuroblastoma Chemotherapy Drugs Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Neuroblastoma Chemotherapy Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 MARKET ANALYSIS BY REGION
4.1 Global Neuroblastoma Chemotherapy Drugs Market Size by Region
4.1.1 Global Neuroblastoma Chemotherapy Drugs Sales in Volume by Region (2017-2028)
4.1.2 Global Neuroblastoma Chemotherapy Drugs Revenue by Region (2017-2028)
4.2 North America Neuroblastoma Chemotherapy Drugs Revenue (2017-2028)
4.3 Europe Neuroblastoma Chemotherapy Drugs Revenue (2017-2028)
4.4 Asia-Pacific Neuroblastoma Chemotherapy Drugs Revenue (2017-2028)
4.5 South America Neuroblastoma Chemotherapy Drugs Revenue (2017-2028)
4.6 Middle East and Africa Neuroblastoma Chemotherapy Drugs Revenue (2017-2028)
5 MARKET SEGMENT BY TYPE
5.1 Global Neuroblastoma Chemotherapy Drugs Sales in Volume by Type (2017-2028)
5.2 Global Neuroblastoma Chemotherapy Drugs Revenue by Type (2017-2028)
5.3 Global Neuroblastoma Chemotherapy Drugs Price by Type (2017-2028)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Neuroblastoma Chemotherapy Drugs Sales in Volume by Application (2017-2028)
6.2 Global Neuroblastoma Chemotherapy Drugs Revenue by Application (2017-2028)
6.3 Global Neuroblastoma Chemotherapy Drugs Price by Application (2017-2028)
7 NORTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION
7.1 North America Neuroblastoma Chemotherapy Drugs Sales by Type (2017-2028)
7.2 North America Neuroblastoma Chemotherapy Drugs Sales by Application (2017-2028)
7.3 North America Neuroblastoma Chemotherapy Drugs Market Size by Country
7.3.1 North America Neuroblastoma Chemotherapy Drugs Sales in Volume by Country (2017-2028)
7.3.2 North America Neuroblastoma Chemotherapy Drugs Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 EUROPE BY COUNTRY, BY TYPE, AND BY APPLICATION
8.1 Europe Neuroblastoma Chemotherapy Drugs Sales by Type (2017-2028)
8.2 Europe Neuroblastoma Chemotherapy Drugs Sales by Application (2017-2028)
8.3 Europe Neuroblastoma Chemotherapy Drugs Market Size by Country
8.3.1 Europe Neuroblastoma Chemotherapy Drugs Sales in Volume by Country (2017-2028)
8.3.2 Europe Neuroblastoma Chemotherapy Drugs Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 ASIA-PACIFIC BY REGION, BY TYPE, AND BY APPLICATION
9.1 Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales by Type (2017-2028)
9.2 Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales by Application (2017-2028)
9.3 Asia-Pacific Neuroblastoma Chemotherapy Drugs Market Size by Region
9.3.1 Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Neuroblastoma Chemotherapy Drugs Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 SOUTH AMERICA BY REGION, BY TYPE, AND BY APPLICATION
10.1 South America Neuroblastoma Chemotherapy Drugs Sales by Type (2017-2028)
10.2 South America Neuroblastoma Chemotherapy Drugs Sales by Application (2017-2028)
10.3 South America Neuroblastoma Chemotherapy Drugs Market Size by Country
10.3.1 South America Neuroblastoma Chemotherapy Drugs Sales in Volume by Country (2017-2028)
10.3.2 South America Neuroblastoma Chemotherapy Drugs Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 MIDDLE EAST & AFRICA BY COUNTRY, BY TYPE, AND BY APPLICATION
11.1 Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Type (2017-2028)
11.2 Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Application (2017-2028)
11.3 Middle East & Africa Neuroblastoma Chemotherapy Drugs Market Size by Country
11.3.1 Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 RAW MATERIAL AND INDUSTRY CHAIN
12.1 Raw Material of Neuroblastoma Chemotherapy Drugs and Key Manufacturers
12.2 Manufacturing Costs Percentage of Neuroblastoma Chemotherapy Drugs
12.3 Neuroblastoma Chemotherapy Drugs Production Process
12.4 Neuroblastoma Chemotherapy Drugs Industrial Chain
13 SALES CHANNEL, DISTRIBUTORS, TRADERS AND DEALERS
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Neuroblastoma Chemotherapy Drugs Typical Distributors
13.3 Neuroblastoma Chemotherapy Drugs Typical Customers
14 RESEARCH FINDINGS AND CONCLUSION
15 APPENDIX
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
1.1 Neuroblastoma Chemotherapy Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Neuroblastoma Chemotherapy Drugs Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Cyclophosphamide
1.2.3 Cisplatin or Carboplatin
1.2.4 Vincristine
1.2.5 Doxorubicin (Adriamycin)
1.2.6 Etoposide
1.2.7 Other
1.3 Market Analysis by Application
1.3.1 Overview: Global Neuroblastoma Chemotherapy Drugs Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Neuroblastoma Chemotherapy Drugs Market Size & Forecast
1.4.1 Global Neuroblastoma Chemotherapy Drugs Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Neuroblastoma Chemotherapy Drugs Sales in Volume (2017-2028)
1.4.3 Global Neuroblastoma Chemotherapy Drugs Price (2017-2028)
1.5 Global Neuroblastoma Chemotherapy Drugs Production Capacity Analysis
1.5.1 Global Neuroblastoma Chemotherapy Drugs Total Production Capacity (2017-2028)
1.5.2 Global Neuroblastoma Chemotherapy Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Neuroblastoma Chemotherapy Drugs Market Drivers
1.6.2 Neuroblastoma Chemotherapy Drugs Market Restraints
1.6.3 Neuroblastoma Chemotherapy Drugs Trends Analysis
2 MANUFACTURERS PROFILES
2.1 Baxter Healthcare
2.1.1 Baxter Healthcare Details
2.1.2 Baxter Healthcare Major Business
2.1.3 Baxter Healthcare Neuroblastoma Chemotherapy Drugs Product and Services
2.1.4 Baxter Healthcare Neuroblastoma Chemotherapy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Ingenus Pharmaceuticals
2.2.1 Ingenus Pharmaceuticals Details
2.2.2 Ingenus Pharmaceuticals Major Business
2.2.3 Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
2.2.4 Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 ANI Pharmaceuticals
2.3.1 ANI Pharmaceuticals Details
2.3.2 ANI Pharmaceuticals Major Business
2.3.3 ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
2.3.4 ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Teva Pharmaceuticals
2.4.1 Teva Pharmaceuticals Details
2.4.2 Teva Pharmaceuticals Major Business
2.4.3 Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
2.4.4 Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Qilu Pharmaceutical
2.5.1 Qilu Pharmaceutical Details
2.5.2 Qilu Pharmaceutical Major Business
2.5.3 Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Product and Services
2.5.4 Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Pfizer
2.6.1 Pfizer Details
2.6.2 Pfizer Major Business
2.6.3 Pfizer Neuroblastoma Chemotherapy Drugs Product and Services
2.6.4 Pfizer Neuroblastoma Chemotherapy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Hikma Pharmaceuticals
2.7.1 Hikma Pharmaceuticals Details
2.7.2 Hikma Pharmaceuticals Major Business
2.7.3 Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
2.7.4 Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Fresenius Kabi
2.8.1 Fresenius Kabi Details
2.8.2 Fresenius Kabi Major Business
2.8.3 Fresenius Kabi Neuroblastoma Chemotherapy Drugs Product and Services
2.8.4 Fresenius Kabi Neuroblastoma Chemotherapy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Accord Healthcare
2.9.1 Accord Healthcare Details
2.9.2 Accord Healthcare Major Business
2.9.3 Accord Healthcare Neuroblastoma Chemotherapy Drugs Product and Services
2.9.4 Accord Healthcare Neuroblastoma Chemotherapy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Viatris
2.10.1 Viatris Details
2.10.2 Viatris Major Business
2.10.3 Viatris Neuroblastoma Chemotherapy Drugs Product and Services
2.10.4 Viatris Neuroblastoma Chemotherapy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 NEUROBLASTOMA CHEMOTHERAPY DRUGS BREAKDOWN DATA BY MANUFACTURER
3.1 Global Neuroblastoma Chemotherapy Drugs Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Neuroblastoma Chemotherapy Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Neuroblastoma Chemotherapy Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Neuroblastoma Chemotherapy Drugs Manufacturer Market Share in 2021
3.4.2 Top 6 Neuroblastoma Chemotherapy Drugs Manufacturer Market Share in 2021
3.5 Global Neuroblastoma Chemotherapy Drugs Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Neuroblastoma Chemotherapy Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 MARKET ANALYSIS BY REGION
4.1 Global Neuroblastoma Chemotherapy Drugs Market Size by Region
4.1.1 Global Neuroblastoma Chemotherapy Drugs Sales in Volume by Region (2017-2028)
4.1.2 Global Neuroblastoma Chemotherapy Drugs Revenue by Region (2017-2028)
4.2 North America Neuroblastoma Chemotherapy Drugs Revenue (2017-2028)
4.3 Europe Neuroblastoma Chemotherapy Drugs Revenue (2017-2028)
4.4 Asia-Pacific Neuroblastoma Chemotherapy Drugs Revenue (2017-2028)
4.5 South America Neuroblastoma Chemotherapy Drugs Revenue (2017-2028)
4.6 Middle East and Africa Neuroblastoma Chemotherapy Drugs Revenue (2017-2028)
5 MARKET SEGMENT BY TYPE
5.1 Global Neuroblastoma Chemotherapy Drugs Sales in Volume by Type (2017-2028)
5.2 Global Neuroblastoma Chemotherapy Drugs Revenue by Type (2017-2028)
5.3 Global Neuroblastoma Chemotherapy Drugs Price by Type (2017-2028)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Neuroblastoma Chemotherapy Drugs Sales in Volume by Application (2017-2028)
6.2 Global Neuroblastoma Chemotherapy Drugs Revenue by Application (2017-2028)
6.3 Global Neuroblastoma Chemotherapy Drugs Price by Application (2017-2028)
7 NORTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION
7.1 North America Neuroblastoma Chemotherapy Drugs Sales by Type (2017-2028)
7.2 North America Neuroblastoma Chemotherapy Drugs Sales by Application (2017-2028)
7.3 North America Neuroblastoma Chemotherapy Drugs Market Size by Country
7.3.1 North America Neuroblastoma Chemotherapy Drugs Sales in Volume by Country (2017-2028)
7.3.2 North America Neuroblastoma Chemotherapy Drugs Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 EUROPE BY COUNTRY, BY TYPE, AND BY APPLICATION
8.1 Europe Neuroblastoma Chemotherapy Drugs Sales by Type (2017-2028)
8.2 Europe Neuroblastoma Chemotherapy Drugs Sales by Application (2017-2028)
8.3 Europe Neuroblastoma Chemotherapy Drugs Market Size by Country
8.3.1 Europe Neuroblastoma Chemotherapy Drugs Sales in Volume by Country (2017-2028)
8.3.2 Europe Neuroblastoma Chemotherapy Drugs Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 ASIA-PACIFIC BY REGION, BY TYPE, AND BY APPLICATION
9.1 Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales by Type (2017-2028)
9.2 Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales by Application (2017-2028)
9.3 Asia-Pacific Neuroblastoma Chemotherapy Drugs Market Size by Region
9.3.1 Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Neuroblastoma Chemotherapy Drugs Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 SOUTH AMERICA BY REGION, BY TYPE, AND BY APPLICATION
10.1 South America Neuroblastoma Chemotherapy Drugs Sales by Type (2017-2028)
10.2 South America Neuroblastoma Chemotherapy Drugs Sales by Application (2017-2028)
10.3 South America Neuroblastoma Chemotherapy Drugs Market Size by Country
10.3.1 South America Neuroblastoma Chemotherapy Drugs Sales in Volume by Country (2017-2028)
10.3.2 South America Neuroblastoma Chemotherapy Drugs Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 MIDDLE EAST & AFRICA BY COUNTRY, BY TYPE, AND BY APPLICATION
11.1 Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Type (2017-2028)
11.2 Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Application (2017-2028)
11.3 Middle East & Africa Neuroblastoma Chemotherapy Drugs Market Size by Country
11.3.1 Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 RAW MATERIAL AND INDUSTRY CHAIN
12.1 Raw Material of Neuroblastoma Chemotherapy Drugs and Key Manufacturers
12.2 Manufacturing Costs Percentage of Neuroblastoma Chemotherapy Drugs
12.3 Neuroblastoma Chemotherapy Drugs Production Process
12.4 Neuroblastoma Chemotherapy Drugs Industrial Chain
13 SALES CHANNEL, DISTRIBUTORS, TRADERS AND DEALERS
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Neuroblastoma Chemotherapy Drugs Typical Distributors
13.3 Neuroblastoma Chemotherapy Drugs Typical Customers
14 RESEARCH FINDINGS AND CONCLUSION
15 APPENDIX
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
LIST OF TABLES
Table 1. Global Neuroblastoma Chemotherapy Drugs Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Neuroblastoma Chemotherapy Drugs Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Baxter Healthcare Basic Information, Manufacturing Base and Competitors
Table 4. Baxter Healthcare Major Business
Table 5. Baxter Healthcare Neuroblastoma Chemotherapy Drugs Product and Services
Table 6. Baxter Healthcare Neuroblastoma Chemotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Ingenus Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 8. Ingenus Pharmaceuticals Major Business
Table 9. Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
Table 10. Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. ANI Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 12. ANI Pharmaceuticals Major Business
Table 13. ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
Table 14. ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Teva Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 16. Teva Pharmaceuticals Major Business
Table 17. Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
Table 18. Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 20. Qilu Pharmaceutical Major Business
Table 21. Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Product and Services
Table 22. Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Pfizer Basic Information, Manufacturing Base and Competitors
Table 24. Pfizer Major Business
Table 25. Pfizer Neuroblastoma Chemotherapy Drugs Product and Services
Table 26. Pfizer Neuroblastoma Chemotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Hikma Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 28. Hikma Pharmaceuticals Major Business
Table 29. Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
Table 30. Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Fresenius Kabi Basic Information, Manufacturing Base and Competitors
Table 32. Fresenius Kabi Major Business
Table 33. Fresenius Kabi Neuroblastoma Chemotherapy Drugs Product and Services
Table 34. Fresenius Kabi Neuroblastoma Chemotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Accord Healthcare Basic Information, Manufacturing Base and Competitors
Table 36. Accord Healthcare Major Business
Table 37. Accord Healthcare Neuroblastoma Chemotherapy Drugs Product and Services
Table 38. Accord Healthcare Neuroblastoma Chemotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Viatris Basic Information, Manufacturing Base and Competitors
Table 40. Viatris Major Business
Table 41. Viatris Neuroblastoma Chemotherapy Drugs Product and Services
Table 42. Viatris Neuroblastoma Chemotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Global Neuroblastoma Chemotherapy Drugs Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 44. Global Neuroblastoma Chemotherapy Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 45. Market Position of Manufacturers in Neuroblastoma Chemotherapy Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 46. Global Neuroblastoma Chemotherapy Drugs Production Capacity by Company, (K Units): 2020 VS 2021
Table 47. Head Office and Neuroblastoma Chemotherapy Drugs Production Site of Key Manufacturer
Table 48. Neuroblastoma Chemotherapy Drugs New Entrant and Capacity Expansion Plans
Table 49. Neuroblastoma Chemotherapy Drugs Mergers & Acquisitions in the Past Five Years
Table 50. Global Neuroblastoma Chemotherapy Drugs Sales by Region (2017-2022) & (K Units)
Table 51. Global Neuroblastoma Chemotherapy Drugs Sales by Region (2023-2028) & (K Units)
Table 52. Global Neuroblastoma Chemotherapy Drugs Revenue by Region (2017-2022) & (USD Million)
Table 53. Global Neuroblastoma Chemotherapy Drugs Revenue by Region (2023-2028) & (USD Million)
Table 54. Global Neuroblastoma Chemotherapy Drugs Sales by Type (2017-2022) & (K Units)
Table 55. Global Neuroblastoma Chemotherapy Drugs Sales by Type (2023-2028) & (K Units)
Table 56. Global Neuroblastoma Chemotherapy Drugs Revenue by Type (2017-2022) & (USD Million)
Table 57. Global Neuroblastoma Chemotherapy Drugs Revenue by Type (2023-2028) & (USD Million)
Table 58. Global Neuroblastoma Chemotherapy Drugs Price by Type (2017-2022) & (US$/Unit)
Table 59. Global Neuroblastoma Chemotherapy Drugs Price by Type (2023-2028) & (US$/Unit)
Table 60. Global Neuroblastoma Chemotherapy Drugs Sales by Application (2017-2022) & (K Units)
Table 61. Global Neuroblastoma Chemotherapy Drugs Sales by Application (2023-2028) & (K Units)
Table 62. Global Neuroblastoma Chemotherapy Drugs Revenue by Application (2017-2022) & (USD Million)
Table 63. Global Neuroblastoma Chemotherapy Drugs Revenue by Application (2023-2028) & (USD Million)
Table 64. Global Neuroblastoma Chemotherapy Drugs Price by Application (2017-2022) & (US$/Unit)
Table 65. Global Neuroblastoma Chemotherapy Drugs Price by Application (2023-2028) & (US$/Unit)
Table 66. North America Neuroblastoma Chemotherapy Drugs Sales by Country (2017-2022) & (K Units)
Table 67. North America Neuroblastoma Chemotherapy Drugs Sales by Country (2023-2028) & (K Units)
Table 68. North America Neuroblastoma Chemotherapy Drugs Revenue by Country (2017-2022) & (USD Million)
Table 69. North America Neuroblastoma Chemotherapy Drugs Revenue by Country (2023-2028) & (USD Million)
Table 70. North America Neuroblastoma Chemotherapy Drugs Sales by Type (2017-2022) & (K Units)
Table 71. North America Neuroblastoma Chemotherapy Drugs Sales by Type (2023-2028) & (K Units)
Table 72. North America Neuroblastoma Chemotherapy Drugs Sales by Application (2017-2022) & (K Units)
Table 73. North America Neuroblastoma Chemotherapy Drugs Sales by Application (2023-2028) & (K Units)
Table 74. Europe Neuroblastoma Chemotherapy Drugs Sales by Country (2017-2022) & (K Units)
Table 75. Europe Neuroblastoma Chemotherapy Drugs Sales by Country (2023-2028) & (K Units)
Table 76. Europe Neuroblastoma Chemotherapy Drugs Revenue by Country (2017-2022) & (USD Million)
Table 77. Europe Neuroblastoma Chemotherapy Drugs Revenue by Country (2023-2028) & (USD Million)
Table 78. Europe Neuroblastoma Chemotherapy Drugs Sales by Type (2017-2022) & (K Units)
Table 79. Europe Neuroblastoma Chemotherapy Drugs Sales by Type (2023-2028) & (K Units)
Table 80. Europe Neuroblastoma Chemotherapy Drugs Sales by Application (2017-2022) & (K Units)
Table 81. Europe Neuroblastoma Chemotherapy Drugs Sales by Application (2023-2028) & (K Units)
Table 82. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales by Region (2017-2022) & (K Units)
Table 83. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales by Region (2023-2028) & (K Units)
Table 84. Asia-Pacific Neuroblastoma Chemotherapy Drugs Revenue by Region (2017-2022) & (USD Million)
Table 85. Asia-Pacific Neuroblastoma Chemotherapy Drugs Revenue by Region (2023-2028) & (USD Million)
Table 86. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales by Type (2017-2022) & (K Units)
Table 87. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales by Type (2023-2028) & (K Units)
Table 88. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales by Application (2017-2022) & (K Units)
Table 89. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales by Application (2023-2028) & (K Units)
Table 90. South America Neuroblastoma Chemotherapy Drugs Sales by Country (2017-2022) & (K Units)
Table 91. South America Neuroblastoma Chemotherapy Drugs Sales by Country (2023-2028) & (K Units)
Table 92. South America Neuroblastoma Chemotherapy Drugs Revenue by Country (2017-2022) & (USD Million)
Table 93. South America Neuroblastoma Chemotherapy Drugs Revenue by Country (2023-2028) & (USD Million)
Table 94. South America Neuroblastoma Chemotherapy Drugs Sales by Type (2017-2022) & (K Units)
Table 95. South America Neuroblastoma Chemotherapy Drugs Sales by Type (2023-2028) & (K Units)
Table 96. South America Neuroblastoma Chemotherapy Drugs Sales by Application (2017-2022) & (K Units)
Table 97. South America Neuroblastoma Chemotherapy Drugs Sales by Application (2023-2028) & (K Units)
Table 98. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Region (2017-2022) & (K Units)
Table 99. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Region (2023-2028) & (K Units)
Table 100. Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue by Region (2017-2022) & (USD Million)
Table 101. Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue by Region (2023-2028) & (USD Million)
Table 102. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Type (2017-2022) & (K Units)
Table 103. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Type (2023-2028) & (K Units)
Table 104. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Application (2017-2022) & (K Units)
Table 105. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Application (2023-2028) & (K Units)
Table 106. Neuroblastoma Chemotherapy Drugs Raw Material
Table 107. Key Manufacturers of Neuroblastoma Chemotherapy Drugs Raw Materials
Table 108. Direct Channel Pros & Cons
Table 109. Indirect Channel Pros & Cons
Table 110. Neuroblastoma Chemotherapy Drugs Typical Distributors
Table 111. Neuroblastoma Chemotherapy Drugs Typical Customers
Table 1. Global Neuroblastoma Chemotherapy Drugs Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Neuroblastoma Chemotherapy Drugs Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Baxter Healthcare Basic Information, Manufacturing Base and Competitors
Table 4. Baxter Healthcare Major Business
Table 5. Baxter Healthcare Neuroblastoma Chemotherapy Drugs Product and Services
Table 6. Baxter Healthcare Neuroblastoma Chemotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Ingenus Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 8. Ingenus Pharmaceuticals Major Business
Table 9. Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
Table 10. Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. ANI Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 12. ANI Pharmaceuticals Major Business
Table 13. ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
Table 14. ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Teva Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 16. Teva Pharmaceuticals Major Business
Table 17. Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
Table 18. Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 20. Qilu Pharmaceutical Major Business
Table 21. Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Product and Services
Table 22. Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Pfizer Basic Information, Manufacturing Base and Competitors
Table 24. Pfizer Major Business
Table 25. Pfizer Neuroblastoma Chemotherapy Drugs Product and Services
Table 26. Pfizer Neuroblastoma Chemotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Hikma Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 28. Hikma Pharmaceuticals Major Business
Table 29. Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
Table 30. Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Fresenius Kabi Basic Information, Manufacturing Base and Competitors
Table 32. Fresenius Kabi Major Business
Table 33. Fresenius Kabi Neuroblastoma Chemotherapy Drugs Product and Services
Table 34. Fresenius Kabi Neuroblastoma Chemotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Accord Healthcare Basic Information, Manufacturing Base and Competitors
Table 36. Accord Healthcare Major Business
Table 37. Accord Healthcare Neuroblastoma Chemotherapy Drugs Product and Services
Table 38. Accord Healthcare Neuroblastoma Chemotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Viatris Basic Information, Manufacturing Base and Competitors
Table 40. Viatris Major Business
Table 41. Viatris Neuroblastoma Chemotherapy Drugs Product and Services
Table 42. Viatris Neuroblastoma Chemotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Global Neuroblastoma Chemotherapy Drugs Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 44. Global Neuroblastoma Chemotherapy Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 45. Market Position of Manufacturers in Neuroblastoma Chemotherapy Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 46. Global Neuroblastoma Chemotherapy Drugs Production Capacity by Company, (K Units): 2020 VS 2021
Table 47. Head Office and Neuroblastoma Chemotherapy Drugs Production Site of Key Manufacturer
Table 48. Neuroblastoma Chemotherapy Drugs New Entrant and Capacity Expansion Plans
Table 49. Neuroblastoma Chemotherapy Drugs Mergers & Acquisitions in the Past Five Years
Table 50. Global Neuroblastoma Chemotherapy Drugs Sales by Region (2017-2022) & (K Units)
Table 51. Global Neuroblastoma Chemotherapy Drugs Sales by Region (2023-2028) & (K Units)
Table 52. Global Neuroblastoma Chemotherapy Drugs Revenue by Region (2017-2022) & (USD Million)
Table 53. Global Neuroblastoma Chemotherapy Drugs Revenue by Region (2023-2028) & (USD Million)
Table 54. Global Neuroblastoma Chemotherapy Drugs Sales by Type (2017-2022) & (K Units)
Table 55. Global Neuroblastoma Chemotherapy Drugs Sales by Type (2023-2028) & (K Units)
Table 56. Global Neuroblastoma Chemotherapy Drugs Revenue by Type (2017-2022) & (USD Million)
Table 57. Global Neuroblastoma Chemotherapy Drugs Revenue by Type (2023-2028) & (USD Million)
Table 58. Global Neuroblastoma Chemotherapy Drugs Price by Type (2017-2022) & (US$/Unit)
Table 59. Global Neuroblastoma Chemotherapy Drugs Price by Type (2023-2028) & (US$/Unit)
Table 60. Global Neuroblastoma Chemotherapy Drugs Sales by Application (2017-2022) & (K Units)
Table 61. Global Neuroblastoma Chemotherapy Drugs Sales by Application (2023-2028) & (K Units)
Table 62. Global Neuroblastoma Chemotherapy Drugs Revenue by Application (2017-2022) & (USD Million)
Table 63. Global Neuroblastoma Chemotherapy Drugs Revenue by Application (2023-2028) & (USD Million)
Table 64. Global Neuroblastoma Chemotherapy Drugs Price by Application (2017-2022) & (US$/Unit)
Table 65. Global Neuroblastoma Chemotherapy Drugs Price by Application (2023-2028) & (US$/Unit)
Table 66. North America Neuroblastoma Chemotherapy Drugs Sales by Country (2017-2022) & (K Units)
Table 67. North America Neuroblastoma Chemotherapy Drugs Sales by Country (2023-2028) & (K Units)
Table 68. North America Neuroblastoma Chemotherapy Drugs Revenue by Country (2017-2022) & (USD Million)
Table 69. North America Neuroblastoma Chemotherapy Drugs Revenue by Country (2023-2028) & (USD Million)
Table 70. North America Neuroblastoma Chemotherapy Drugs Sales by Type (2017-2022) & (K Units)
Table 71. North America Neuroblastoma Chemotherapy Drugs Sales by Type (2023-2028) & (K Units)
Table 72. North America Neuroblastoma Chemotherapy Drugs Sales by Application (2017-2022) & (K Units)
Table 73. North America Neuroblastoma Chemotherapy Drugs Sales by Application (2023-2028) & (K Units)
Table 74. Europe Neuroblastoma Chemotherapy Drugs Sales by Country (2017-2022) & (K Units)
Table 75. Europe Neuroblastoma Chemotherapy Drugs Sales by Country (2023-2028) & (K Units)
Table 76. Europe Neuroblastoma Chemotherapy Drugs Revenue by Country (2017-2022) & (USD Million)
Table 77. Europe Neuroblastoma Chemotherapy Drugs Revenue by Country (2023-2028) & (USD Million)
Table 78. Europe Neuroblastoma Chemotherapy Drugs Sales by Type (2017-2022) & (K Units)
Table 79. Europe Neuroblastoma Chemotherapy Drugs Sales by Type (2023-2028) & (K Units)
Table 80. Europe Neuroblastoma Chemotherapy Drugs Sales by Application (2017-2022) & (K Units)
Table 81. Europe Neuroblastoma Chemotherapy Drugs Sales by Application (2023-2028) & (K Units)
Table 82. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales by Region (2017-2022) & (K Units)
Table 83. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales by Region (2023-2028) & (K Units)
Table 84. Asia-Pacific Neuroblastoma Chemotherapy Drugs Revenue by Region (2017-2022) & (USD Million)
Table 85. Asia-Pacific Neuroblastoma Chemotherapy Drugs Revenue by Region (2023-2028) & (USD Million)
Table 86. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales by Type (2017-2022) & (K Units)
Table 87. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales by Type (2023-2028) & (K Units)
Table 88. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales by Application (2017-2022) & (K Units)
Table 89. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales by Application (2023-2028) & (K Units)
Table 90. South America Neuroblastoma Chemotherapy Drugs Sales by Country (2017-2022) & (K Units)
Table 91. South America Neuroblastoma Chemotherapy Drugs Sales by Country (2023-2028) & (K Units)
Table 92. South America Neuroblastoma Chemotherapy Drugs Revenue by Country (2017-2022) & (USD Million)
Table 93. South America Neuroblastoma Chemotherapy Drugs Revenue by Country (2023-2028) & (USD Million)
Table 94. South America Neuroblastoma Chemotherapy Drugs Sales by Type (2017-2022) & (K Units)
Table 95. South America Neuroblastoma Chemotherapy Drugs Sales by Type (2023-2028) & (K Units)
Table 96. South America Neuroblastoma Chemotherapy Drugs Sales by Application (2017-2022) & (K Units)
Table 97. South America Neuroblastoma Chemotherapy Drugs Sales by Application (2023-2028) & (K Units)
Table 98. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Region (2017-2022) & (K Units)
Table 99. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Region (2023-2028) & (K Units)
Table 100. Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue by Region (2017-2022) & (USD Million)
Table 101. Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue by Region (2023-2028) & (USD Million)
Table 102. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Type (2017-2022) & (K Units)
Table 103. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Type (2023-2028) & (K Units)
Table 104. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Application (2017-2022) & (K Units)
Table 105. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Application (2023-2028) & (K Units)
Table 106. Neuroblastoma Chemotherapy Drugs Raw Material
Table 107. Key Manufacturers of Neuroblastoma Chemotherapy Drugs Raw Materials
Table 108. Direct Channel Pros & Cons
Table 109. Indirect Channel Pros & Cons
Table 110. Neuroblastoma Chemotherapy Drugs Typical Distributors
Table 111. Neuroblastoma Chemotherapy Drugs Typical Customers
LIST OF FIGURES
Figure 1. Neuroblastoma Chemotherapy Drugs Picture
Figure 2. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Type in 2021
Figure 3. Cyclophosphamide
Figure 4. Cisplatin or Carboplatin
Figure 5. Vincristine
Figure 6. Doxorubicin (Adriamycin)
Figure 7. Etoposide
Figure 8. Other
Figure 9. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Application in 2021
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Other
Figure 13. Global Neuroblastoma Chemotherapy Drugs Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 14. Global Neuroblastoma Chemotherapy Drugs Revenue and Forecast (2017-2028) & (USD Million)
Figure 15. Global Neuroblastoma Chemotherapy Drugs Sales (2017-2028) & (K Units)
Figure 16. Global Neuroblastoma Chemotherapy Drugs Price (2017-2028) & (US$/Unit)
Figure 17. Global Neuroblastoma Chemotherapy Drugs Production Capacity (2017-2028) & (K Units)
Figure 18. Global Neuroblastoma Chemotherapy Drugs Production Capacity by Geographic Region: 2022 VS 2028
Figure 19. Neuroblastoma Chemotherapy Drugs Market Drivers
Figure 20. Neuroblastoma Chemotherapy Drugs Market Restraints
Figure 21. Neuroblastoma Chemotherapy Drugs Market Trends
Figure 22. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Manufacturer in 2021
Figure 23. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Manufacturer in 2021
Figure 24. Neuroblastoma Chemotherapy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 25. Top 3 Neuroblastoma Chemotherapy Drugs Manufacturer (Revenue) Market Share in 2021
Figure 26. Top 6 Neuroblastoma Chemotherapy Drugs Manufacturer (Revenue) Market Share in 2021
Figure 27. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Region (2017-2028)
Figure 28. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Region (2017-2028)
Figure 29. North America Neuroblastoma Chemotherapy Drugs Revenue (2017-2028) & (USD Million)
Figure 30. Europe Neuroblastoma Chemotherapy Drugs Revenue (2017-2028) & (USD Million)
Figure 31. Asia-Pacific Neuroblastoma Chemotherapy Drugs Revenue (2017-2028) & (USD Million)
Figure 32. South America Neuroblastoma Chemotherapy Drugs Revenue (2017-2028) & (USD Million)
Figure 33. Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue (2017-2028) & (USD Million)
Figure 34. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2017-2028)
Figure 35. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Type (2017-2028)
Figure 36. Global Neuroblastoma Chemotherapy Drugs Price by Type (2017-2028) & (US$/Unit)
Figure 37. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2017-2028)
Figure 38. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Application (2017-2028)
Figure 39. Global Neuroblastoma Chemotherapy Drugs Price by Application (2017-2028) & (US$/Unit)
Figure 40. North America Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2017-2028)
Figure 41. North America Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2017-2028)
Figure 42. North America Neuroblastoma Chemotherapy Drugs Sales Market Share by Country (2017-2028)
Figure 43. North America Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country (2017-2028)
Figure 44. United States Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Canada Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Mexico Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Europe Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2017-2028)
Figure 48. Europe Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2017-2028)
Figure 49. Europe Neuroblastoma Chemotherapy Drugs Sales Market Share by Country (2017-2028)
Figure 50. Europe Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country (2017-2028)
Figure 51. Germany Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. France Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. United Kingdom Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Russia Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Italy Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Market Share by Region (2017-2028)
Figure 57. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2017-2028)
Figure 58. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Market Share by Region (2017-2028)
Figure 59. Asia-Pacific Neuroblastoma Chemotherapy Drugs Revenue Market Share by Region (2017-2028)
Figure 60. China Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Japan Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Korea Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. India Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Southeast Asia Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Australia Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. South America Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2017-2028)
Figure 67. South America Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2017-2028)
Figure 68. South America Neuroblastoma Chemotherapy Drugs Sales Market Share by Country (2017-2028)
Figure 69. South America Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country (2017-2028)
Figure 70. Brazil Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Argentina Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2017-2028)
Figure 73. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2017-2028)
Figure 74. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Market Share by Region (2017-2028)
Figure 75. Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue Market Share by Region (2017-2028)
Figure 76. Turkey Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Egypt Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Saudi Arabia Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. South Africa Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. Manufacturing Cost Structure Analysis of Neuroblastoma Chemotherapy Drugs in 2021
Figure 81. Manufacturing Process Analysis of Neuroblastoma Chemotherapy Drugs
Figure 82. Neuroblastoma Chemotherapy Drugs Industrial Chain
Figure 83. Sales Channel: Direct Channel vs Indirect Channel
Figure 84. Methodology
Figure 85. Research Process and Data Source
Figure 1. Neuroblastoma Chemotherapy Drugs Picture
Figure 2. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Type in 2021
Figure 3. Cyclophosphamide
Figure 4. Cisplatin or Carboplatin
Figure 5. Vincristine
Figure 6. Doxorubicin (Adriamycin)
Figure 7. Etoposide
Figure 8. Other
Figure 9. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Application in 2021
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Other
Figure 13. Global Neuroblastoma Chemotherapy Drugs Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 14. Global Neuroblastoma Chemotherapy Drugs Revenue and Forecast (2017-2028) & (USD Million)
Figure 15. Global Neuroblastoma Chemotherapy Drugs Sales (2017-2028) & (K Units)
Figure 16. Global Neuroblastoma Chemotherapy Drugs Price (2017-2028) & (US$/Unit)
Figure 17. Global Neuroblastoma Chemotherapy Drugs Production Capacity (2017-2028) & (K Units)
Figure 18. Global Neuroblastoma Chemotherapy Drugs Production Capacity by Geographic Region: 2022 VS 2028
Figure 19. Neuroblastoma Chemotherapy Drugs Market Drivers
Figure 20. Neuroblastoma Chemotherapy Drugs Market Restraints
Figure 21. Neuroblastoma Chemotherapy Drugs Market Trends
Figure 22. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Manufacturer in 2021
Figure 23. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Manufacturer in 2021
Figure 24. Neuroblastoma Chemotherapy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 25. Top 3 Neuroblastoma Chemotherapy Drugs Manufacturer (Revenue) Market Share in 2021
Figure 26. Top 6 Neuroblastoma Chemotherapy Drugs Manufacturer (Revenue) Market Share in 2021
Figure 27. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Region (2017-2028)
Figure 28. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Region (2017-2028)
Figure 29. North America Neuroblastoma Chemotherapy Drugs Revenue (2017-2028) & (USD Million)
Figure 30. Europe Neuroblastoma Chemotherapy Drugs Revenue (2017-2028) & (USD Million)
Figure 31. Asia-Pacific Neuroblastoma Chemotherapy Drugs Revenue (2017-2028) & (USD Million)
Figure 32. South America Neuroblastoma Chemotherapy Drugs Revenue (2017-2028) & (USD Million)
Figure 33. Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue (2017-2028) & (USD Million)
Figure 34. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2017-2028)
Figure 35. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Type (2017-2028)
Figure 36. Global Neuroblastoma Chemotherapy Drugs Price by Type (2017-2028) & (US$/Unit)
Figure 37. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2017-2028)
Figure 38. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Application (2017-2028)
Figure 39. Global Neuroblastoma Chemotherapy Drugs Price by Application (2017-2028) & (US$/Unit)
Figure 40. North America Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2017-2028)
Figure 41. North America Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2017-2028)
Figure 42. North America Neuroblastoma Chemotherapy Drugs Sales Market Share by Country (2017-2028)
Figure 43. North America Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country (2017-2028)
Figure 44. United States Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Canada Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Mexico Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Europe Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2017-2028)
Figure 48. Europe Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2017-2028)
Figure 49. Europe Neuroblastoma Chemotherapy Drugs Sales Market Share by Country (2017-2028)
Figure 50. Europe Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country (2017-2028)
Figure 51. Germany Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. France Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. United Kingdom Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Russia Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Italy Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Market Share by Region (2017-2028)
Figure 57. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2017-2028)
Figure 58. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Market Share by Region (2017-2028)
Figure 59. Asia-Pacific Neuroblastoma Chemotherapy Drugs Revenue Market Share by Region (2017-2028)
Figure 60. China Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Japan Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Korea Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. India Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Southeast Asia Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Australia Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. South America Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2017-2028)
Figure 67. South America Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2017-2028)
Figure 68. South America Neuroblastoma Chemotherapy Drugs Sales Market Share by Country (2017-2028)
Figure 69. South America Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country (2017-2028)
Figure 70. Brazil Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Argentina Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2017-2028)
Figure 73. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2017-2028)
Figure 74. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Market Share by Region (2017-2028)
Figure 75. Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue Market Share by Region (2017-2028)
Figure 76. Turkey Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Egypt Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Saudi Arabia Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. South Africa Neuroblastoma Chemotherapy Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. Manufacturing Cost Structure Analysis of Neuroblastoma Chemotherapy Drugs in 2021
Figure 81. Manufacturing Process Analysis of Neuroblastoma Chemotherapy Drugs
Figure 82. Neuroblastoma Chemotherapy Drugs Industrial Chain
Figure 83. Sales Channel: Direct Channel vs Indirect Channel
Figure 84. Methodology
Figure 85. Research Process and Data Source
